AGIO
Agios Pharmaceuticals Inc
Halal Rating :
Last Price
$32.39
Last updated:
Market Cap
-
7D Change
-5.57%
1 Year Change
49.81%
Company Overview
Industries
Exchange
Next Earnings Date
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics in the field of cellular metabolism. The company's main focus is on developing treatments for rare genetic diseases and cancer. Their lead product is PYRUKYND® (mitapivat), which is approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $8.96m | $111.78m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $8.62m | $114.43m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $8.19m | $100.26m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Agios Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.